NeutralLOW severityHealthcare & Pharma94d ago

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock — $AVTX one-month chart
$AVTX daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about AVTX. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · avalo therapeuticsEvent risk Moderate
  • Legal: Filed with SEC
  • Clear: key person, regulatory, security, operational, financial integrity
From here · last month’s volatility 168% a year
Now $7.00Week $5.35–$8.65 (±23.6%)Month $3.61–$10.39 (±48.4%)
Early signals (1) — filed with the SEC or first reported, not yet widely covered
  • Legal · SEC 8-K, Item 1.02, Nov 5: Filed: the termination of a material agreement. View filing →
Ask Wook AI

Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.

Wook analysis

What it means

Key points
  • What to watch: The headline hangs on one number ($13,580) — one data point is a snapshot, so the trailing trend is the context it needs.
  • How the stock is trading: $AVTX -5.02% in the latest session.
  • Timing: It came out on a weekend, so the change shown is Friday's and Monday's open is the first chance to trade on it. Market holidays are not detected.
Amount$13,580

Where the stock stands

Avalo Therapeutics ($AVTX) fell 5.02% to $7.00 in the latest session. Over the past month it is down 39.6%. It now sits 71% under the 52-week high of $24.27 and 7.2% above the year's low of $6.53, close to the bottom of its range. The year's high was 3.7 times its low, which makes double-digit swings fairly routine here.

How much coverage it is getting

This story is more than a month old. Since then Wook has filed one newer story on Avalo Therapeutics in the last 30 days. It reads neutral.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $AVTX page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $AVTX: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on August 15, 2026. $AVTX has moved -64.91% ($19.95 to $7.00). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy